Predictive Oncology Inc. logo

Predictive Oncology Inc.

POAI | NASDAQ
Chart Builder DCF Calculator
$4.91
+$0.29 (+6.28%)
At close: May 20, 2026, 12:45 PM ET

Company Profile

Predictive Oncology Inc. (POAI), an organization driven by expertise and data, is dedicated to pioneering individualized cancer treatments through the application of artificial intelligence, primarily within the United States. The company conducts its operations across four distinct divisions: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics division offers extensive clinical diagnostic services, including tumor drug response assessments and genomic profiling, alongside contract research focused on patient-centered drug discovery. This latter service leverages active learning technology for foundational discovery, clinical and translational research, clinical trials, and the development and validation of diagnostics. Meanwhile, the zPREDICTA division excels in crafting organ-specific disease models, providing three-dimensional reconstructions of human tissues that accurately mirror various disease states and simulate drug responses, particularly for evaluating anticancer agents. The Soluble segment delivers services centered on High-Throughput Self-Interaction Chromatography, an automated system proficient at screening additives and excipients in protein formulations to ensure the creation of soluble and physically stable biologic therapeutics. This segment also provides protein stability analysis, specialized kits for swift identification of soluble formulations, and proprietary technologies for the detection and elimination of bacterial endotoxins. The Skyline division markets the STREAMWAY System, a fully automated, wall-mounted device designed to substantially minimize healthcare staff's exposure to blood and other infectious fluids in clinical environments. Furthermore, this division conducts research and development and supplies specialized media that supports the ex-vivo growth of cancer cells while maintaining their original DNA/RNA and proteomic signatures. Founded in 2002, the company was formerly known as Precision Therapeutics Inc. until it adopted the name Predictive Oncology Inc. in June 2019. Its corporate headquarters are situated in Eagan, Minnesota.

Key Executives

Name Position
Raymond F. Vennare Chief Executive Officer & Chairman
Joshua Blacher Interim Chief Financial Officer
Arlette H. Uihlein FCAP Senior Vice President of Translational Medicine & Drug Discovery and Medical Director
Lawrence J. DeLucas D.Sc O.D Senior Vice President of Biologics
Sara Turken Senior Vice President & General Counsel
Thomas McLaughlin Chief Investment Officer

Latest SEC Filings

Date Type Title
Sep 17, 2026 8-K Current Report
Sep 09, 2026 4 Filing
Sep 09, 2026 4 Filing
Sep 09, 2026 4 Filing
Sep 09, 2026 4 Filing
Sep 09, 2026 4 Filing
Sep 09, 2026 4 Filing
Aug 17, 2026 8-K Current Report
Aug 14, 2026 10-Q Quarterly Report
Aug 14, 2026 8-K Current Report
View All SEC Filings ➞
Predictive Oncology Inc.
Predictive Oncology Inc. logo
Country United States
IPO Date May 3, 2010
Industry Medical - Instruments & Supplies
Sector Healthcare
Employees 23
CEO Raymond F. Vennare

Contact Details

2915 Commers Drive Pittsburgh, Minnesota 55121 United States

Stock Details

Ticker Symbol POAI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001446159
CUSIP Number 74039M408
ISIN Number US74039M4087
SIC Code 3842

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.